

Professor Gisela Kobelt

CURRICULUM VITAE

Personal details

Name: Gisela Kobelt

Education: PhD

Professional experience

Current position:

- NDA HTA Advisory Board Member
- Founder and president of European Health Economics SAS
- Author of an introductory guide to economic evaluation for non-specialists that is now available in several languages (from the Office of Health Economics in London, www.ohe.org)
- Since 1996, Gisela organises and directs an annual intensive training course entitled 'Health Economics of Pharmaceuticals and other Medical Interventions'

Previous positions:

- Course director of the executive course in 'Strategic Health Economics' at the Stockholm School of Economics
- Vice-President, Corporate Health Economics, at the Pharmacia & Upjohn Corporate Management Center in Stockholm and London
- Created and headed the Health Economics department at Sandoz (now Novartis) in Basel (Switzerland). She initially joined Sandoz as project manager in R&D and was subsequently transferred for three years to Sandoz USA
- Director of Human Resources, Finance and Administration at the Merrell Dow Research Center in Strasbourg (France) for six year

Areas of Expertise

- Master's degree from the University of Strasbourg (France)
- MBA from the Institute for Management Development (IMD/IMEDE) in Lausanne (Switzerland)
- PhD in Health Economics from the Karolinska Institute in Stockholm (Sweden)

Publications

Scientific Papers:

1. Lekander I, Kobelt G, Svarvar P, Ljung T, vanVollenhoven R, Borgström F. The Comparison of Trial-Based and Registry Data-Based Cost-Effectiveness of Infliximab Treatment for Rheumatoid Arthritis in Sweden using a Modeling Approach. *Value in Health* 2013;16:251-258
2. Augustin AJ, Sahel JA, Cerully L, Texier B, Buchholz P, Kobelt G. Treating retinal vein occlusions in France, Germany and Italy. An analysis of treatment patterns, resource consumption and costs. *Eur J Ophthalmol* 2012;22(5):776-784
3. Blahova J, Havradova E, Kalinicik T, Dolezal T, Kobelt G. Cost of multiple sclerosis in the Czech Republic: The COMS study. *Multiple Sclerosis Journal* 2012;18:659-665
4. Augustin M, Alvaro-Garcia JM, Bagot M, Hillmann O, van de Kerkhof PCM, Kobelt G, Maccarone M, Naldi L, Schellekens H. A framework for improving the quality of care for people with psoriasis. *J Eur Acad Dermatology Venerology* 2012;26(suppl 4):1-16.
5. Lekander I, Borgström F, Lysholm J, vonVollenhofen R, Lindblad S, Geborek P, Kobelt G. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. *European Journal of Health Economics*, online September 19, 2012

Please contact Professor Kobelt for details on further publications.

Reports:

1. Kobelt G, Kasten G F. The burden of multiple sclerosis and access to innovative treatments in Europe. www.comparatorreports.se
2. Kobelt G, Kasteng, F. The burden of rheumatoid arthritis and access to innovative treatments in Europe. www.comparatorreports.se
3. Kobelt G, Berg J, Atherley D, Hadjimichael O, Jonsson B (2004) Costs and Quality of Life in Multiple Sclerosis. A Cross-Sectional Study in the USA. Stockholm School of Economics, EFI Research Report 594.
4. Kobelt G, Jönsson L, Fredrikson S, Jönsson B (2001). Cost-utility analysis of Interferon-Beta-1b in the treatment of different types of MS. Stockholm School of Economics, EFI Research Report No 459, Stockholm.
5. Kobelt G, Lindgren P, Smala A, Jönsson B (2000). Costs and Quality of Life in Multiple Sclerosis. A cross-sectional study in Germany. Stockholm School of Economics, EFI Research Report No 399, Stockholm.
6. Kobelt G, Lindgren P, Parkin D, Francis D, Johnson M, Bates D, Jönsson B (2000). Costs and Quality of Life in Multiple Sclerosis. A cross-sectional study in the United Kingdom. Stockholm School of Economics, EFI Research Report No 398, Stockholm.
7. Jönsson B, Jönsson L, Kobelt G (1999). Modelling disease progression and the effect of treatment in secondary progressive MS. Stockholm School of Economics, EFI Research Report ISBN 91-7278-520-X, Stockholm.

8. Jönsson B, Jönsson L, Kobelt G (1999). Modelling disease progression and the effect of treatment in secondary progressive MS. Stockholm School of Economics, EFI Research Report ISBN 91-7278-520-X, Stockholm.
9. Kobelt G (1997) The demand for new, safe, efficacious and cost-effective medicines – can the pharmaceutical industry deliver? In: Economic Aspects of Biotechnologies Related to Human Health. OECD Report, GD(97)205.
10. Jönsson B, Kaarela K, Kobelt G (1997). Economic consequences of the progression of Rheumatoid Arthritis. A Markov Model. Stockholm School of Economics, EFI research paper 6574, Stockholm.
11. Gerdtham UG, Williamson T, Kobelt G, Jönsson B (1997) Observational costing study in primary open angle glaucoma. Results for Canada. Stockholm School of Economics, EFI research paper 6569, Stockholm.
12. Kobelt G (1997) The demand for new, safe, efficacious and cost-effective medicines – can the pharmaceutical industry deliver? In: Economic Aspects of Biotechnologies Related to Human Health. OECD Report, GD(97)205.
13. Gerdtham UG, Håga A, Karlsson G, Kobelt G, Jönsson B (1996). Observational costing study in primary open angle glaucoma. Results for USA and Sweden. Stockholm School of Economics, EFI research paper 6566, Stockholm.
14. Kobelt G (1994). Health Economics - An Industry View. European J.of Pharmaceutical Sciences, 69.

Books:

1. Kobelt G. The Social and Economic Impact of Rheumatoid Arthritis: Health Burden and Economic Cost. In : Rheumatoid Arthritis. Hochberg, Silman, Smolen, Weinblatt, Weisman Editors. Mosby Elsevier, Philadelphia. 2009:p 83-89.
2. Health Economics - An introduction to economic evaluation. Office of Health Economics, London, UK. Second edition 2002
3. An observational study and cost simulation model of treatment strategies in patients with ocular hypertension and primary open angle glaucoma in 9 countries. In Primary Open Angle Glaucoma: Differences in International Treatment Patterns and Costs. In: Jönsson B and Krieglstein GK, Editors. Pages 11- 126. ISIS Medical Media, Oxford.
4. Kobelt G (2001) Outcomes Research: A guide to economic evaluation in multiple sclerosis. PPS Europe, Worthing, UK.